Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 103,221,456
  • Shares Outstanding, K 1,306,270
  • Annual Sales, $ 30,390 M
  • Annual Income, $ 13,501 M
  • 36-Month Beta 1.13
  • Price/Sales 3.80
  • Price/Cash Flow 6.27
  • Price/Book 4.09

Price Performance

See More
Period Period Low Period High Performance
1-Month
71.61 +12.07%
on 12/29/17
81.59 -1.64%
on 01/16/18
+4.68 (+6.19%)
since 12/15/17
3-Month
70.05 +14.56%
on 11/14/17
82.47 -2.69%
on 10/19/17
+0.30 (+0.38%)
since 10/16/17
52-Week
63.76 +25.86%
on 06/16/17
86.27 -6.98%
on 09/08/17
+7.18 (+9.83%)
since 01/13/17

Most Recent Stories

More News
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 1.13%

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $79.52 to a high of $81.59. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of...

GILD : 80.25 (+1.56%)
Watch for Gilead Sciences to Potentially Pullback After Gaining 1.13% Yesterday

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $79.52 to a high of $81.59. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of...

GILD : 80.25 (+1.56%)
Global T-Cell Immunotherapy Market for Cancer & Pipeline Analysis 2018-2030 Featuring Key Players - Novartis, Gilead Sciences and Juno Therapeutics

The "Global T-Cell Immunotherapy Market for Cancer & Pipeline Analysis " report has been added to ResearchAndMarkets.com's offering.

NVS : 86.73 (+0.09%)
GILD : 80.25 (+1.56%)
Can Biotech Keep Last Year's Momentum Alive in 2018?

The biotech sector performed impressively in 2017 and the momentum is expected to continue in 2018 driven by new drug approvals. Acquisitions will also remain in focus.

CELG : 104.82 (-1.11%)
VRTX : 155.71 (-1.41%)
EXEL : 29.65 (-2.40%)
GILD : 80.25 (+1.56%)
REGN : 370.21 (+0.89%)
AMGN : 185.54 (+0.27%)
ALXN : 124.48 (+1.44%)
Big Pharma CEOs Speak About Impact of Tax Reform on M&A

This week, senior executives of some large drug companies discussed the impact of tax reform on mergers and acquisition and their plans to use the excess cash at the JP Morgan HealthCare conference.

CELG : 104.82 (-1.11%)
JNJ : 146.86 (+0.75%)
MRK : 62.07 (+5.81%)
LLY : 85.29 (-1.94%)
AGN : 178.66 (+1.48%)
GILD : 80.25 (+1.56%)
BIIB : 338.85 (+0.86%)
Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus

Focus this week was on preliminary results and 2018 outlooks provided by several companies including Celgene (CELG) at a healthcare conference.

CELG : 104.82 (-1.11%)
VRTX : 155.71 (-1.41%)
AXON : 2.11 (+0.96%)
ABBV : 102.49 (+2.14%)
GILD : 80.25 (+1.56%)
ACOR : 25.05 (-3.09%)
REGN : 370.21 (+0.89%)
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 3.39%

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $74.57 to a high of $77.09. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of...

GILD : 80.25 (+1.56%)
FDA Approvals Surge in 2017: Here's a Look at the Numbers

There was a significant surge in FDA approvals in 2017 with the regulatory body giving its nod to 46 novel drugs plus gene-based therapies like Novartis's (NVS) Kymriah. Here is a closer look at the numbers...

LLY : 85.29 (-1.94%)
GWPH : 130.30 (-1.27%)
NVS : 86.73 (+0.09%)
GILD : 80.25 (+1.56%)
RHHBY : 30.6800 (-3.45%)
REGN : 370.21 (+0.89%)
AMGN : 185.54 (+0.27%)
Galapagos Reports Topline Data From Osteoarthritis Study

Galapagos' (GLPG) osteoarthritis candidate, GLPG1972, reduces level of ARGS neoepitope, a cartilage breakdown biomarker, by more than half in an early stage study.

VRTX : 155.71 (-1.41%)
ABBV : 102.49 (+2.14%)
GILD : 80.25 (+1.56%)
GLPG : 110.86 (+2.29%)
Celgene to Acquire Impact Biomedicines to Boost Pipeline

Celgene (CELG) announced that it will acquire Impact Biomedicines to bolster its oncology pipeline given the recent series of setbacks.

AGIO : 68.80 (-8.40%)
CELG : 104.82 (-1.11%)
INCY : 91.65 (-2.57%)
GILD : 80.25 (+1.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. They strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and...

See More

Key Turning Points

2nd Resistance Point 82.52
1st Resistance Point 81.39
Last Price 80.25
1st Support Level 79.32
2nd Support Level 78.38

See More

52-Week High 86.27
Last Price 80.25
Fibonacci 61.8% 77.67
Fibonacci 50% 75.01
Fibonacci 38.2% 72.36
52-Week Low 63.76

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.